-
公开(公告)号：US06350613B1
公开(公告)日：2002-02-26
申请号：US09252153
申请日：1999-02-18
IPC分类号： G01N3100
CPC分类号： G01N15/1475 , G01N33/5094 , G01N2015/0076 , G01N2015/0092 , G01N2015/1472 , G01N2015/1497 , Y10T436/10 , Y10T436/101666
摘要： Target nucleated cells, and target cells containing remnant ribosomal material, which are present in a quiescent anticoagulated whole blood sample are optically detected, enumerated, and analyzed in a sample chamber that has a varying through plane thickness due to convergent opposing sample chamber walls. At least one of the convergent walls of the chamber is transparent so that the blood sample can be observed. The chamber's varying thickness produces a first lesser thickness region in the chamber wherein individual red cells and quiescent monolayers of red cells in the sample will reside after the sample is introduced into and fills the chamber. Larger formed constituents such as white blood cells and nucleated red blood cells present in the sample will reside in greater thickness regions of the chamber, and non-nucleated red cells which reside in such greater thickness regions will agglomerate to form rouleaux. By admixing fluorescent dyes with the blood sample, target cells in the sample can be enumerated and differentiated by means of a scanning instrument which is able to measure different wave length color signals emitted from the target cells in the sample, and differentiate the target cells one from another by reason of the nature of the emitted color signals.
摘要翻译： 目标有核细胞和含有剩余核糖体材料的靶细胞，其存在于静止抗凝全血样品中，由于收敛的相对的样品室壁在具有不同的平面厚度的样品室中进行光学检测，计数和分析。 室的收敛壁中的至少一个是透明的，使得可以观察血液样本。 室的不同厚度在腔室中产生第一较小的厚度区域，其中在将样品引入并填充室之后，样品中红细胞的各个红细胞和静止单层将驻留。 存在于样品中的较大的成形组分如白细胞和有核红细胞将驻留在室的较大厚度区域中，并且驻留在这样较厚的区域中的未成核的红细胞将聚集形成rouleaux。 通过将荧光染料与血液样品混合，样品中的靶细胞可以通过能够测量样品中靶细胞发射的不同波长颜色信号的扫描仪器进行枚举和分化，并将靶细胞分化为一 由于发射的颜色信号的性质，从另一个。
-
62.发明授权公开(公告)号：US06197523B1
公开(公告)日：2001-03-06
申请号：US08976886
申请日：1997-11-24
IPC分类号： G01N33574
CPC分类号： G01N15/042 , G01N33/56972 , G01N33/57484 , G01N2015/045 , Y10S436/813
摘要： A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence or absence of target cancer cells and/or hematologic progenitor cells which are known to circulate in blood. The analysis is performed in a sample of centrifuged anticoagulated whole blood. The analysis involves both morphometric and epitopic examination of the blood sample while the blood sample is disposed in a centrifuged blood sampling tube. The epitopic analysis of the presence or absence of cancer cells relies on the detection of epitopes which are known to present only on cancer cells; and the epitopic analysis of the presence or absence of hematologic progenitor cells relies on the detection of epitopes which are known to present only on hematologic progenitor cells. The targeted epitopes on the target cell types are epitopes which are also known to be absent on normal circulating blood cells; and the target cancer cell epitopes are epitopes which are known to be absent on target hematologic progenitor cells. Fluorophors with distinct emissions are coupled with antibodies which are directed against the targeted epitopes. The morphometric analysis is performed by staining the cells in the blood sample with an intracellular stain such as acridine orange which highlights the intracellular cell structure. Both the morphometric and epitopic analyses are preferably performed at or near the platelet layer of the expanded buffy coat in the centrifuged blood sample. The morphometric analysis and/or the epitopic analysis may be performed under magnification both visually and/or photometrically.
摘要翻译： 用于分析血液的方法使得能够在放大下分离，检测，枚举和确认已知在血液中循环的靶癌细胞和/或血液祖细胞的存在或不存在。 在离心的抗凝全血样品中进行分析。 该分析涉及血液样品的形态测定和表征检查，同时将血液样品置于离心取样管中。 癌细胞存在或不存在的代表性分析依赖于已知仅存在癌细胞的表位的检测; 并且血液祖细胞存在或不存在的表征分析依赖于已知仅存在血液祖细胞的表位的检测。 目标细胞类型上的靶向表位是已知在正常循环血细胞上不存在的表位; 并且目标癌细胞表位是已知在靶血液祖细胞上不存在的表位。 具有明显排放的荧光素与针对靶向表位的抗体相结合。 通过用细胞内染色剂如吖啶橙染色血液样品中的细胞进行形态测定分析，突出细胞内细胞结构。 形态测定和表征分析优选在离心血液样品中在扩张的血沉棕黄层的血小板层或其附近进行。 形态测定分析和/或表征分析可以在视觉上和/或光度下放大进行。
-
公开(公告)号：US5776710A
公开(公告)日：1998-07-07
申请号：US771507
申请日：1996-12-23
申请人： Robert A. Levine , Stephen C. Wardlaw , Leon W. M. M. Terstappen , Kristen L. Manion , Rodolfo R. Rodriguez , Adrien P. Malick , Subhash Dhanesar , Stephen J. Lovell , Alvydas J. Ozinskas
发明人： Robert A. Levine , Stephen C. Wardlaw , Leon W. M. M. Terstappen , Kristen L. Manion , Rodolfo R. Rodriguez , Adrien P. Malick , Subhash Dhanesar , Stephen J. Lovell , Alvydas J. Ozinskas
IPC分类号： G01N33/543 , B01L3/14 , G01N33/49 , G01N33/537 , G01N33/569 , G01N33/58 , G01N33/558
CPC分类号： B01L3/5021 , G01N33/491 , G01N33/5375 , G01N33/56972 , G01N33/585 , Y10S435/81 , Y10S435/967 , Y10S435/971 , Y10S435/973 , Y10S436/805 , Y10S436/81 , Y10S436/824 , Y10S436/829 , Y10T436/111666
摘要： A patient's health may be diagnosed by centrifuging blood samples in a transparent tube, which tube contains one or more bodies or groups of bodies such as floats, inserts, liposomes, or plastic beads of different densities. Each density-defined body carries analyte-capture binding materials such as antigens or antibodies, which are specific to an epitope, or other specific high affinity binding site on a target analyte which target analyte may be in the blood or other sample being tested; and the level of which analyte is indicative of the patient's health. At least one labeled binding material which is also specific to an epitope, or other specific high affinity binding site on the target analyte is added to the sample so as to form labeled binding material/analyte/body complexes in the sample. Upon centrifugation, the complexes will settle out in different areas in the tube according to the respective density of the body or bodies; and the degree of label emission of the complex layers can enable qualitative and/or quantitative analyses of the sample to be made. Unbound labeled binding materials will be separated from the complexed layers by the washing action of ascending or descending components of the sample during the centrifugation step. Unbound labeled binding material will thus not interfere with the analysis.
摘要翻译： 可以通过将透明管中的血液样品离心来诊断患者的健康，该管包含一个或多个不同密度的浮体，插入物，脂质体或塑料珠的主体或组。 每个密度定义的身体携带分析物 - 捕获结合材料，例如抗原或抗体，其对靶分析物是特异性的，或靶分析物上的其它特异性高亲和力结合位点，其目标分析物可能在待测试的血液或其他样品中; 并且其分析物的水平表示患者的健康。 将至少一种对靶分析物上的表位或其他特异性高亲和力结合位点特异性的标记结合物质加入到样品中，以便在样品中形成标记的结合材料/分析物/身体复合物。 离心后，复合物将根据身体或身体的相应密度沉淀在管中的不同区域; 并且复合层的标签发射程度可以使得要进行样品的定性和/或定量分析。 通过在离心步骤期间样品的上升或下降组分的洗涤作用，未结合的标记结合材料将从复合层分离。 因此，未结合的标签结合材料不会影响分析。
-
公开(公告)号：US5593848A
公开(公告)日：1997-01-14
申请号：US335310
申请日：1994-11-07
IPC分类号： G01N33/48 , A61K9/127 , G01N33/532 , G01N33/534 , G01N33/537 , G01N33/538 , G01N33/544 , G01N33/533 , G01N33/536
CPC分类号： G01N33/5375 , G01N33/538 , Y10S436/829
摘要： An improved assay of target components in a sample utilizes specific gravity-altering particles which are attached to the target components by specific antibodies. The attached specific gravity-altering particles are preferably liposomes which will buoy or sink the targets to a common level in the specimen sample when the latter has been centrifuged in a transparent tube. The liposomes can provide an accentuated and more pronounced indication of the presence of the targets in the sample due to their ability to contain many multiples of fluorescent or non-fluorescent dye molecules with minimal steric interference with the attached antibodies' binding ability.
摘要翻译： 样品中目标组分的改进测定利用通过特异性抗体附着于靶组分的比重改变颗粒。 附着的比重改变颗粒优选是脂质体，当将后者已经在透明管中离心时，其将标本浮标或将目标物吸收到标本样品中的共同水平。 脂质体可以提供样品中靶标存在的突出和更显着的指示，因为它们具有包含许多倍数的荧光或非荧光染料分子的能力，其具有与所附抗体结合能力的最小空间干扰。
-
公开(公告)号：US5321975A
公开(公告)日：1994-06-21
申请号：US770875
申请日：1991-10-04
CPC分类号： G01N15/042 , G01N33/491 , G01N2015/045
摘要： Erythrocytes exist in vivo in a continuous cell subset gradient of density, with the youngest cells being the lightest. A blood sample is centrifuged in a transparent tube containing plastic beads which are selected to include groups of beads wherein each group has a different sharply defined specific gravity, and which are distributed within the range of red cell densities. The beads form spaced well-defined bands in the erythrocyte layer, which bands form boundaries between the different cell subset layers. Measurements of the lengths of the different cell subset layers are then made to quantify the red cell subsets in the patient's blood.
摘要翻译： 红细胞在体内存在于密度连续的细胞亚群梯度中，最小的细胞是最轻的。 将血液样品在含有塑料珠的透明管中离心，所述塑料珠被选择为包括珠粒组，其中每组具有不同的明确比重，并且分布在红细胞密度的范围内。 珠粒在红细胞层中形成间隔明确的带，该带形成不同细胞子集层之间的边界。 然后测量不同细胞子集层的长度以量化患者血液中的红细胞亚群。
-
66.发明授权
公开(公告)号：US5252460A
公开(公告)日：1993-10-12
申请号：US783397
申请日：1991-10-28
IPC分类号： G01N33/569 , G01N33/574 , G01N33/537 , G01N33/538
CPC分类号： G01N33/569 , G01N33/56966 , G01N33/574 , Y10S436/80 , Y10S436/805 , Y10S436/81 , Y10S436/813 , Y10S436/824
摘要： A biologic sample such as feces, sputum, cervical tissue, pleural fluids, exudates, cytologic specimens, or the like, is tested for the presence or absence of: ova; parasites; microorganisms; inflammatory, neoplastic tissue cells; or other target materials which are indicative of infestation, disease or infection. The sample is mixed with a buffer fluid and placed in a transparent tube which contains a volume-constricting cylindrical insert for gravimetric separation of components of the sample. The mixture is centrifuged, and the annular space between the insert and tube bore is examined under magnification for the presence of the target materials.
摘要翻译： 对生物样品如粪便，痰液，宫颈组织，胸膜液，渗出液，细胞学标本等进行测试，以确定是否存在：ova; 寄生虫 微生物 炎性，肿瘤组织细胞; 或指示感染，疾病或感染的其他目标材料。 将样品与缓冲液混合并置于含有体积收缩的圆柱形插入物的透明管中，用于重量分离样品组分。 将混合物离心，并且在放大下检查插入件和管孔之间的环形空间以存在目标材料。
-
67.发明授权Quantification of fibrinogen in whole blood samples contained in a tube using a float to separate materials 失效在使用浮选分离材料的管中包含的全血样品中的纤维蛋白质的量化
公开(公告)号：US5137832A
公开(公告)日：1992-08-11
申请号：US636677
申请日：1991-01-02
CPC分类号： G01N15/042
摘要： Quantification of blood plasma fibrinogen content is made in a sample of anticoagulated whole blood contained in a sampling tube. The tube is a transparent centrifuge tube which contains a sample constituent layer-elongating float. The blood sample is centrifuged in the tube containing the float, and various cell constituent measurements are made. The centrifuged sample is then heated and recentrifuged to cause the precipitated fibrinogen to layer out on top of the float remote from the buffy coat band in the plasma layer. The thickness of the fibrinogen band is then measured, whereby quantification of the fibrinogen content of the blood sample can be made by a precalibrated instrument.
-
公开(公告)号：US5086784A
公开(公告)日：1992-02-11
申请号：US579274
申请日：1990-09-05
IPC分类号： G01N33/48 , A61B5/145 , A61B5/15 , A61M1/02 , B01L3/14 , G01N20060101 , G01N1/00 , G01N33/15 , G01N33/49
CPC分类号： G01N33/491 , B01L3/50215 , G01N15/042 , G01N15/05 , A61B5/15003 , A61B5/150351 , A61B5/150389 , A61B5/150473 , A61B5/150755 , A61B5/153
摘要： Centrifuged material layer measurements are made in an evacuated glass or clear plastic tube which contains a float. When possibly contaminated materials, such as blood, are being tested the use of the evacuated tube allows the measurements to be made without the technician being exposed to the blood. The tubes are large enough to hold approximately one ml of blood, and are filled with an inert gas at low pressure. Dimensional tolerances relative to those of a capillary tube are relaxed for the tube and float due to the larger sample capacity. The cell bands are stabilized by a layer of a flowable material which settles onto the plasma layer during centrifugation and forms a pellicle thereon.
摘要翻译： 离心材料层的测量在包含浮子的真空玻璃或透明塑料管中进行。 当可能受污染的材料（例如血液）被测试时，使用真空管允许在没有技术人员暴露于血液的情况下进行测量。 管足够大以容纳约1ml血液，并在低压下填充惰性气体。 由于较大的样品容量，相对于毛细管的尺寸公差会因管和浮子而松弛。 细胞带通过可流动的材料层稳定，其在离心过程中沉降到等离子体层上并在其上形成防护薄膜组件。
-
公开(公告)号：US4804518A
公开(公告)日：1989-02-14
申请号：US704962
申请日：1985-02-25
CPC分类号： G01N33/726 , G01N33/528 , Y10S435/805
摘要： The device consists of a base sheet of impermeable plastic such as vinyl, or the like, and a guaiac stool receptor sheet adhesively secured thereto. The base sheet is sufficiently larger than the receptor sheet so to form an impermeable skirt which surrounds the receptor sheet so as to form an hermetic barrier protecting the receptor sheet on the underneath one of two of the devices when stacked one on top of the other. A performance/control monitor is included on the device. The monitor includes a peroxidatively active material such as hematin, or the like, which confirms the reactively of the guaiac-impregnated sheet, as well as the activity of the peroxide developing solution. The monitor material is kept out of reactive contact with the guaiac receptor sheet until the developer reagent is applied to the device. A stack of the devices is packed in a sealed container of plastic, or the like, so that the individual devices can be removed from the container one at a time. The devices are designed for use in the physician's office for reception of stool smears taken manually on a rubber glove or finger cot by the physician from patients.
-
公开(公告)号：US20200278341A1
公开(公告)日：2020-09-03
申请号：US16812959
申请日：2020-03-09
摘要： A method and device for analyzing a hematologic sample centrifuged within a capillary tube is provided. The device includes a tube holder, a sample imaging device, a processor, and a sample data display. The sample imaging device is operable to create a digital image of the sample within a region of the tube. The region is defined by substantially all of the radial width and axial length of the sample residing within the internal cavity of the tube in the region where the float resides after centrifugation. The sample imaging device is operable to produce signals representative of the image. The processor is adapted to produce information relating to bands of interest within the image based on the signals from the sample imaging device. The sample data display is adapted to display the results therefrom and/or a digital image of the sample within the region.
-
-
-
-
-
-
-
-
-
搜索结果
209 条记录 (耗时 0.028 秒)
